How Moderna, Inc. Makes Money

Moderna generates revenue through three primary streams that together produced $1.944 billion in fiscal year 2025: Net Product Sales, Collaboration Revenue, and Other Revenue. Net Product Sales constitute the overwhelming majority of the business, generating $1.818 billion in 2025, down from $3.109 billion in 2024, and representing approximately 94% of Total Revenue. This stream includes direct sales of Spikevax, mNEXSPIKE, and mRESVIA to government procurement agencies, retail pharmacies, hospital systems, and international distributors. In 2025, U.S. product sales totaled $1.2 billion, or 62% of net product sales, while international sales contributed $745 million, or 38%. The U.S. revenue concentration reflects the seasonal nature of COVID and RSV vaccination, with demand concentrated in fall and winter months. The Other Revenue stream, which includes grant revenue, collaboration milestones, and stand-ready manufacturing revenue from long-term strategic partnerships, added $126 million in 2025. Collaboration Revenue from partnerships with Merck, AstraZeneca, and other biotechnology companies has historically contributed to Moderna's financials but declined as the company focused on proprietary products. The loss of Spikevax Product Sales would be catastrophic to Moderna's current financial architecture; COVID vaccine sales generated $1.8 billion in 2025 and remain the company's dominant revenue source, though declining at double-digit rates as the market transitions from pandemic to endemic. The mNEXSPIKE next-generation vaccine, approved in 2025, represented approximately 24% of all U.S. retail COVID vaccinations in its first year, generating an estimated $400-500 million in revenue. The mRESVIA RSV vaccine, approved in 2024 and expanded to high-risk adults 18-59 in 2025, generated negligible sales amid competition from Pfizer's Abrysvo and GSK's Arexvy, which together dominate the $1.5 billion RSV vaccine market. Moderna's cost of sales was $868 million in 2025, or 48% of net product sales, including $88 million in third-party royalties and $291 million in inventory write-downs. This cost structure reflects the challenges of maintaining pandemic-scale manufacturing capacity for seasonal demand, with unutilized manufacturing capacity and wind-down costs contributing to margin pressure. The company's gross margin is negative when including inventory write-downs and capacity underutilization, a structural problem that the cost-reduction program aims to address. Research and development expenses were $3.1 billion in 2025, a 31% decrease from $4.5 billion in 2024, reflecting the wind-down of large Phase 3 respiratory programs and portfolio prioritization. Selling, general, and administrative expenses were $1.0 billion in 2025, a 13% decrease from 2024. The company's business model depends on a global commercial infrastructure of approximately 1,000 sales and marketing employees who operate in 18 countries, selling to government health agencies, pharmacy chains, and physician practices. The model also depends on maintaining manufacturing capacity at facilities in Massachusetts, New Hampshire, and international sites in the UK, Canada, and Australia, even as demand fluctuates seasonally. The company's revenue model is therefore characterized by high fixed costs, seasonal demand concentration, and a transition from government advance purchase agreements to retail commercial sales, creating significant financial volatility. The company's supply chain strategy includes dual sourcing for critical raw materials such as lipid components and nucleotides, reducing dependence on single suppliers and ensuring continuity of production. The regional distribution centers in the United States, Europe, and Asia-Pacific reduce shipping costs and improve product availability for seasonal vaccination campaigns. The company's quality systems, which were built to support pandemic-scale production of billions of doses, provide a foundation for maintaining compliance across multiple facilities and products, but also create fixed costs that are difficult to reduce proportionally with volume declines. The company's patient support programs, including financial assistance for uninsured patients and vaccination education initiatives, aim to improve access and adherence, but these programs add to the cost structure without generating direct revenue. The company's digital health initiatives, including mobile applications for vaccination scheduling and reminder systems, could improve patient engagement and provide commercial insights, but require ongoing investment in software development and data analytics. The company's environmental commitments, including carbon neutrality goals for manufacturing operations, reflect stakeholder expectations but add to operational costs. The integration of these operational capabilities into a cohesive commercial strategy is a significant challenge for a company that has historically focused on scientific development rather than commercial execution. The business model must therefore evolve from a pandemic-focused, government-contracting model to a diversified, commercially-driven model that can generate sustainable profits in competitive markets.

Moderna's growth strategy rests on four pillars that collectively aim to deliver cash break-even by 2028 and establish a sustainable biotechnology enterprise. First, respiratory vaccine franchise expansion requires maintaining COVID vaccine share through mNEXSPIKE strain updates, growing mRESVIA RSV sales through expanded indications and international partnerships, and launching the seasonal flu vaccine (mRNA-1010) to capture share of the $5 billion global flu market. The company has secured long-term agreements with Mexico and Taiwan for respiratory vaccines and is prioritizing Europe as a significant market despite a competitor contract still in effect. Second, pipeline diversification into oncology and rare diseases depends on advancing mRNA-4157 in melanoma with Merck, expanding into other tumor types, and progressing mRNA-3704 and mRNA-3927 for methylmalonic acidemia and propionic acidemia. The oncology strategy leverages Moderna's ability to encode patient-specific neoantigens, creating personalized vaccines that could command premium pricing. Third, cost reduction and operational efficiency targets $1.5 billion in annual operating expense reductions by 2027, achieved through R&D portfolio prioritization, manufacturing rightsizing, workforce reduction, and supplier contract renegotiations. The company has already exceeded its 2025 cost-reduction target by $200 million and expects additional savings in 2026. Fourth, geographic expansion and manufacturing localization involves operating newly opened facilities in the UK, Canada, and Australia to produce locally manufactured vaccines, reducing logistics costs and meeting national procurement preferences. The company also plans to begin selling locally manufactured products in the UK and Australia in 2026, which is the largest driver of international growth. Each of these pillars carries specific financial targets: respiratory vaccines must grow from $1.8 billion in 2025 to $3-4 billion by 2028; oncology and rare diseases must generate initial revenue by 2027-2028; and operating expenses must decline to $3.5 billion annually from $5.0 billion in 2025. The growth strategy is underpinned by the $6 billion cash position, which provides funding for two years of development, but also creates pressure to achieve milestones before requiring additional capital. The company's ability to pivot from pandemic-scale operations to a leaner, focused model will determine whether it can execute this strategy successfully. The company's ability to execute this strategy while managing cash burn, regulatory risk, and commercial execution will determine whether it can achieve the 2028 cash break-even target. The strategy also includes investments in digital health and patient engagement, including mobile applications and reminder systems that could improve vaccination rates and brand loyalty. The company's data science capabilities, which were developed during the pandemic to track vaccine distribution and effectiveness, could be leveraged for commercial insights and patient targeting. The manufacturing quality systems, which were built to pandemic standards, provide a foundation for maintaining compliance across multiple facilities and products. The company's regulatory affairs team, which managed the rapid approval of Spikevax, has experience with accelerated pathways that could be applied to future products. The growth strategy is therefore not merely a collection of product launches but an integrated approach that leverages the company's platform capabilities, manufacturing infrastructure, scientific talent, and strategic partnerships to create sustainable competitive advantages. The success of this integrated approach depends on flawless execution across multiple dimensions, including clinical development, regulatory approval, manufacturing scale-up, commercial launch, and cost management. The company's ability to maintain focus and discipline while navigating these challenges will determine whether it can complete the transformation from pandemic contractor to diversified biotechnology enterprise. The company's data analytics capabilities, which were developed during the pandemic, could be leveraged for commercial insights, patient targeting, and product development. The digital health initiatives, including mobile applications and reminder systems, could improve vaccination rates and brand loyalty. The manufacturing quality systems, built to pandemic standards, provide a foundation for maintaining compliance across multiple facilities and products. The regulatory affairs team, which managed the rapid approval of Spikevax, has experience with accelerated pathways that could be applied to future products. The patient support programs, including financial assistance and vaccination education, aim to improve access and adherence. The ESG commitments, including carbon neutrality and diversity goals, reflect stakeholder expectations and could attract investors and employees. The integration of these capabilities into a cohesive commercial strategy is essential for achieving sustainable growth. The company's ability to execute this integrated strategy while managing cash burn, regulatory risk, and competitive pressure will determine whether it can complete the transformation from pandemic contractor to diversified biotechnology enterprise.